We read with interest the recent article by Böcker and colleagues in JCMM [1] . As [1] . Unlike the approach taken by Böcker and colleagues, the protocol should therefore be well suited for scale-up to high-throughput, good manufacturing practice, standards and can be applied to the polyclonal populations currently explored for clinical cell therapy. 
Fig. 1 (A) Lentiviral transduction of non-adherent murine mesenchymal stem cells (MSC). MSC were exposed to VSV-G pseudotyped green fluorescent protein (GFP) expressing lentivirus for 1 hr at the indicated multiplicities of infection (MOI), alternatively in adherence after plating 16-24 hrs earlier (open symbols), or in suspension (closed symbols). (B) Gene

